It seems like the second OGX-011 paper is also out. Randomized Phase 2 Trial of Custirsen (OGX-011) with Docetaxel or Mitoxantrone in Patients with Metastatic Castrate-Resistant Prostate Cancer: CUOG Trial P06c http://clincancerres.aacrjournals.org/content/early/2011/07/23/1078-0432.CCR-11-0859(If you use a mobile device, you can access the paper for free). PR will probably come in few daysAlso:http://pharmastrategyblog.com/2011/08/custirsen-a-new-treatment-for-castrate-resistant-prostate-cancer.html/
(TTPP) ratio of 10.0 months versus 5 months should be representative of what to expect in pain trials?Dendreon's fiasco and Medicare cuts are hurting Biotech across the board. Patience folks this too shall pass.